Methods and compositions for inhibiting cancer cell growth

Patent metadata

Field	Value
Publication number	US-11078256-B2
Application number	US-201916452178-A
Country	US
Kind code	B2
Filing date	Jun 25, 2019
Priority date	Jun 26, 2018
Publication date	Aug 3, 2021
Grant date	Aug 3, 2021

Abstract

Described are methods and compositions that provide for generating synthetic or recombinant proline rich peptides. In some aspects, p1978 compositions are used to inhibit breast cancer cell growth and thus provided is a method for treating and preventing breast cancer cell growth in a mammal.

First claim

What is claimed is:

1. A method of treating or preventing a cancer in a subject comprising administering an effective amount of a composition comprising a recombinant polypeptide comprising the amino acid sequence of p1978 (SEQ ID NO: 1).

2. The method of claim 1 , wherein the cancer is a breast cancer.

3. The method of claim 2 , wherein the breast cancer is triple negative breast cancer.

4. The method of claim 1 , wherein the composition is administered by intravenous injection or catheter delivery.

5. The method of claim 2 , wherein the composition is administered by intravenous injection or catheter delivery.

6. The method of claim 3 , wherein the composition is administered by intravenous injection or catheter delivery.

7. The method of claim 1 , wherein the recombinant polypeptide is a fusion protein comprising the amino acid sequence of p1978 (SEQ ID NO: 1) and a heterologous polypeptide sequence.

8. The method of claim 1 , wherein the recombinant polypeptide is no more than 50 amino acids in length.

9. The method of claim 1 , wherein the recombinant polypeptide is no more than 20 amino acids in length.

10. The method of claim 1 , wherein the N-terminus, the C-terminus or both are blocked.

Assignees

• Univ Texas

Inventors

• Streckfus Charles F

Classifications

• C07K14/47 Primary

  from mammals · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K9/19

  lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)} · CPC title

• C07K14/8146 Primary

  Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP · CPC title